CWM
PTGX icon

CIBC World Markets’s Protagonist Therapeutics PTGX Stock Holding History

CIBC World Markets’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$336K Buy
+3,851
New +$315K ﹤0.01% 917
2025
Q2 		$396K Sell
7,173
-6,005
-46% -$288K ﹤0.01% 969
2025
Q1 		$637K Buy
13,178
+7,710
+141% +$323K 0.01% 891
2024
Q4 		$211K Buy
+5,468
New +$238K ﹤0.01% 1102
2024
Q2 		– Sell
-200,000
Closed -$5.79M – 781
2024
Q1 		$5.79M Buy
+200,000
New +$5.44M 0.04% 288

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CIBC World Markets's PTGX Position: Q4 2025 in Review

CIBC World Markets opened a new position in Protagonist Therapeutics (PTGX) in Q4 2025: 3,851 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings. This is a return to the name: CIBC World Markets previously reported a position in PTGX as recently as Q2 2025.

CIBC World Markets first reported a position in PTGX in Q1 2024 and has held it in 5 quarters since. The position peaked at $5.79M in Q1 2024. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • CIBC World Markets held 3,851 shares of Protagonist Therapeutics worth $336K as of Q4 2025.
  • Protagonist Therapeutics was a new CIBC World Markets position in Q4 2025.
  • Protagonist Therapeutics made up ﹤0.01% of CIBC World Markets's portfolio in Q4 2025, its #917 holding.
  • CIBC World Markets first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • CIBC World Markets's Protagonist Therapeutics position peaked at $5.79M in Q1 2024.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.